For example, in clinical trials for leukemia, treatment with T cells bearing chimeric antigen receptors targeting CD19 has been shown to result in impressive and sustained response rates.[3] In addition, almost all multiple myeloma patients in a clinical trial with T‐cell chimeric antigen receptors (CAR‐T) cells targeting the B cell maturation antigen (BCMA) showed a complete or nearly complete response.[4]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.